Guidelines include strong recommendations for monoclonal antibodies and JAK inhibitors

Incorporation of religion into cultural humility training recommended, as well as dermatology education at community events

Mohs micrographic surgery was only done on 32.3 percent of the keratinocyte carcinomas that qualified based on AUC score

However, differences between acupuncture and sham acupuncture, wait-list control did not meet threshold for minimal clinically important difference

Considerable shortages of 2.5, 10 mg minoxidil reported by pharmacies in Washington, D.C., Maryland, and Virginia

Specialty training linked to increased tendency to diagnose atypical melanocytic proliferations as pT1a melanomas

Increased risk seen for any skin cancer, keratinocyte carcinoma, squamous cell carcinoma, basal cell carcinoma, and melanoma

Software improvements show high sensitivity across skin cancer types, including melanoma

Effect seen on patients' daily and work life

Approval of the biosimilar allows for interchangeable use with Stelara in both adult and pediatric patients

No increased risk observed for all-cause mortality, MACE, VTE versus placebo/active comparator in dermatologic conditions

Patients with nonulcerated tumors have better survival than incipiently ulcerated cases in univariable analysis

Histopathologic findings included sprinkled distribution of small hyperchromatic lymphocytes in the upper epidermal section

Adolescents with atopic dermatitis have higher odds of being bullied at higher frequency after adjustment for demographics, atopic comorbidities

Treatment efficacy seen in primary end points of itch response and Investigator's Global Assessment response

12-week benefits include high rates of skin clearance, meaningful itch relief

Studies demonstrate potential benefit of vitamins B5 and D, botanical extracts (green tea), probiotics, and ω-3 fatty acids

Alternative regimen of vismodegib 150 mg daily for seven days followed by 21-day drug holiday provides therapeutic effect

The once-daily triple-combination topical acne treatment is approved for use in patients 12 years and older

Faces with acne rated as less attractive, trustworthy, confident, successful, dominant, and happy

The groundbreaking injectable biologic agent demonstrates unprecedented efficacy in the treatment of psoriasis.